Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
WORKING PAPERS
December 16, 2021
How should governments and donors engage with the growing private sector in education in developing countries? Enrolment in private schools now exceeds 50 percent at the primary level in many major urban centres across Africa and Asia. Whilst the majority of these schools are small and independently...
CGD NOTES
November 12, 2007
The President's Emergency Plan for AIDS Relief (PEPFAR) provides more than $5 billion per year to prevent and treat HIV/AIDS. Exactly how is that money spent? Donors, recipients, and even PEPFAR staff are often left guessing, because much of the extensive data the U.S. government collects on the pro...
HIV/AIDS MONITOR ANALYSIS
October 10, 2007
Donor funding for HIV/AIDS has skyrocketed in the last decade: from US$ 300 million in 1996 to US$ 8.9 billion in 2006. Yet, surprisingly little is known about how this money is spent. Following the Funding for HIV/AIDS, by CGD's HIV/AIDS Monitor team, analyzes the policies and practices of the worl...
REPORTS
May 29, 2007
This report of CGD's Global Health Forecasting Working Group, which was convened in early 2006 by senior fellow and director of programs Ruth Levine to sort out why demand forecasting has been so problematic, provides an elegant analysis of the problem and a sensible agenda for action. Their report ...
BRIEFS
May 18, 2007
Achieving better health in poor countries depends in part on giving companies that produce drugs, vaccines and diagnostics incentives to invest in their production by improving their ability to forecast which products will be purchased by whom in what quantities. This brief reviews the findings of C...
HIV/AIDS MONITOR ANALYSIS
March 05, 2007
In response to both public health imperative and unprecedented political pressure, aid to fight HIV/AIDS has increased massively in recent years: global funding to combat the disease in low- and middle-income countries has more than tripled since 2001, from $2.1 billion to an estimated $8.9 billion ...